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ABSTRACT
Severe hemolytic anemia in Basenji dogs secondary to pyruvate kinase deficiency can be corrected by allogeneic
hematopoietic cell transplantation (HCT) from littermates with normal hematopoiesis after conventional
myeloablative or nonmyeloablative conditioning regimens. If the levels of donor chimerism were low (<20%)
after nonmyeloablative HCT, there was only partial correction of the hemolytic anemia. We next addressed
whether allogeneic cell therapy after nonmyeloablative HCT would convert mixed to full hematopoietic
chimerism, achieve sustained remission from hemolysis, and prevent progression of marrow fibrosis and liver
cirrhosis. Three pyruvate kinase–deficient dogs were given HCT from their respective dog leukocyte antigen–
identical littermates after nonmyeloablative conditioning with 200 cGy of total body irradiation. Postgrafting
immunosuppression consisted of mycophenolate mofetil and cyclosporine. All 3 dogs engrafted and had mixed
hematopoietic chimerism with donor levels ranging from 12% to 55% in bone marrow. In 2 of the 3 dogs, there
were decreases in the levels of donor chimerism so that at 25 weeks after nonmyeloablative HCT, hemolysis
recurred that was associated with increased reticulocyte counts. All 3 dogs then had 2 serial infusions of donor
lymphocytes (DLI) from their respective donors at least 20 weeks apart to convert from mixed to full donor
chimerism. Both dogs with recurrence of hemolytic anemia after nonmyeloablative HCT achieved higher
levels of donor chimerism, with donor contributions ranging from 47% to 62% in the bone marrow and 50%
to 69% and 16% to 25% in the granulocyte and mononuclear cell fractions of the peripheral blood, respectively,
and with remission of the hemolytic anemia. One dog responded after the first DLI, and 5 weeks after the
second DLI, the other dog converted to full donor chimerism. At last follow-up, all these dogs showed clinical
improvement, as determined by increasing hematocrits and normal reticulocyte counts. Analysis of the marrow
3 years after HCT showed normal cellularity, a normal myeloid-erythroid ratio, and no or minimal marrow
fibrosis. Liver biopsies demonstrated normal histologies with no or minimal fibrosis. We conclude that DLI
after nonmyeloablative HCT can increase the levels of donor cells contributing to hematopoiesis in recipients,
inducing remissions of the hemolytic process and preventing complications associated with iron overload.
© 2003 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Pyruvate kinase (PK) deﬁciency in dogs results in
severe hemolytic anemia, which in turn results in a
hortened life span because of both progressive my-
loﬁbrosis and liver cirrhosis [1,2]. Marrow transplan-74ally normal, dog leukocyte antigen (DLA)–identical
ittermates after conventional high-dose conditioning
orrected the hemolytic anemia, prevented the devel-
pment of liver cirrhosis, and reversed the myeloﬁ-
rosis and iron overload [3,4]. These observations—
hat the symptoms and sequelae of iron overload andoi:10.1016/j.bbmt.2003.08.005ation of dogs with PK deﬁciency from hematologi-
liver cirrhosis associated with severe hemolytic anemia
could be ameliorated by conventional allogeneic mar-
row transplantation—set the stage for the ﬁrst suc-
cessful transplantation of allogeneic marrow in a hu-
man patient with thalassemia major [5]. Subsequently,
this regimen was used for patients with other red
blood cell disorders, such as sickle cell disease [6,7].
However, the risks of transplant-related complica-
tions, including those related to the myeloablative
conditioning regimen, have made physicians hesitant
to use this approach widely in patients with red blood
cell disorders.
Recently, we reported that mixed hematopoietic
chimerism established after nonmyeloablative condi-
tioning and marrow transplantation was effective in
correcting or delaying the development of myeloﬁ-
brosis and liver cirrhosis in dogs with PK deﬁciency
[8]. The clinical responses correlated with the degrees
of donor hematopoietic chimerism. A low degree of
donor chimerism was not sufﬁcient to prevent contin-
ued hemolysis. We previously reported that mixed
hematopoietic chimerism in dogs not affected with
PK deﬁciency remained stable even after infusions of
donor lymphocytes (DLI) [9]. However, if DLI was
administered from donors that were sensitized to re-
cipient-speciﬁc minor histocompatibility antigens, full
hematopoietic chimerism could be induced in recipi-
ents. It was hypothesized in that study that suppressor
cells in recipients with mixed chimerism prevented
primary allorecognition and subsequent sensitization
of newly infused T cells from nonsensitized donors.
However, T cells in the DLI from donors sensitized to
recipient minor histocompatibility antigens bypassed
or overwhelmed this suppressor cell mechanism re-
sponsible for maintaining the state of mixed hemato-
poietic chimerism, resulting in the conversion to full
donor chimerism. Therefore, in the next phase of
these studies, PK-deﬁcient dogs with mixed hemato-
poietic chimerism after nonmyeloablative hematopoi-
etic cell transplantation (HCT) were given DLI from
donors that had been sensitized to the recipients to
induce full donor hematopoietic chimerism.
MATERIALS AND METHODS
Experimental Animals
Three dogs, a Beagle/minimongrel and 2 Basenji/
Lhasa Apsos (7-11 months old; 6-14 kg body weight)
were raised either at the Scott-Ritchey Research Cen-
ter, Auburn University (Auburn, AL; n  2) or at the
Fred Hutchinson Cancer Research Center (n  1).
None of the dogs with PK deﬁciency had received
transfusions of blood products before HCT. They
were dewormed and vaccinated for rabies, distemper,
leptospirosis, hepatitis, and parvovirus. They were
housed in an American Association for Accreditation
of Laboratory Animal Care–accredited facility in stan-
dard indoor runs and were provided commercial dog
chow and chlorinated tap water ad libitum. Animal
holding areas were maintained at 21°C  1°C with
50%  10% relative humidity, with at least 15 air
changes per hour of 100% conditioned fresh air. The
dogs were on a 12-hour light/dark full-spectrum light-
ing cycle with no twilight. Research was conducted
according to the principles outlined in the Guide for
the Care and Use of Laboratory Animals prepared by the
National Academy of Sciences, National Research
Council. The research protocol was approved by the
Institutional Animal Care and Use Committee of the
Fred Hutchinson Cancer Research Center.
PK Genotype Assessment
PK deﬁciency in dogs that results in hemolytic
anemia is an autosomal recessive disorder. The mu-
tant R-type PK gene results from a single nucleotide
deletion (C433). The PK genotype for PK deﬁciency
in dogs was conﬁrmed by genetic testing as previously
described [10,11].
Histocompatibility Assessment
Littermate donor-recipient pairs were chosen on
the basis of identity by highly polymorphic major
histocompatibility complex class I and II microsatellite
markers [12]. In addition, speciﬁc DLA-DRB1 allelic
identity was determined by direct sequencing [13].
Bone Marrow Transplantation and Supportive
Care
Total Body Irradiation, Postirradiation Care, and
Postgrafting Immunosuppression. Recipient dogs with
PK deﬁciency were given 200 cGy of total body irra-
diation at 7 cGy/min from 2 opposing cobalt 60
sources (n  2) or from a Clinac 4 linear accelerator
(n  1; JM Co., San Jose, CA) [8,14,15]. Donors were
DLA-identical littermates not affected by PK deﬁ-
ciency. Donor marrow was infused intravenously at
doses of 2.2 to 2.7  109 cells per kilogram (median,
2.4  109 cells per kilogram) within 4 hours of total
body irradiation. The day of marrow grafting was
designated as day 0. Recipients were given cyclospor-
ine 15 mg/kg twice daily orally on days 1 to 35 and
mycophenolate mofetil 10 mg/kg twice daily subcuta-
neously on days 0 to 27 after transplantation.
All 3 dogs were given standard postgrafting care
that included oral nonabsorbable antibiotics 3 times
daily, neomycin sulfate, and polymyxin sulfate com-
bined with systemic enroﬂoxacin, which were admin-
istered from day 5 until the day of white blood cell
(WBC) count recovery to 1000/L. Red blood cell
and platelet transfusions from unrelated donors were
given clinically as indicated. All transfused blood
products were irradiated with 2200 cGy from a cesium
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137 source. The dogs’ clinical status was assessed
twice daily.
Hematology. Hematology examinations consisting
of complete blood counts and WBC differentials were
performed at least twice before HCT and for a min-
imum of 5 days per week subsequently until recovery
of red blood cell, granulocyte, and platelet counts, and
then they were generally performed once a week until
4 to 6 months after HCT. The samples were collected
into a tube containing EDTA. Automated hemato-
logic analyses of blood samples were performed on a
Sysmex E 2500 (Baxter, Chicago, IL). Blood smears
were stained with Wright-Giemsa for WBC differen-
tials and with new methylene blue for manual reticu-
locyte counts.
Marrow Biopsy, Aspiration, and Liver Biopsy. Mar-
row for transplantation was aspirated from the donors
under general anesthesia through long needles in-
serted into humeri and femora, and for bone marrow
evaluations, dogs were sedated [8]. Marrow aspiration
and biopsies were performed before HCT, 25 weeks
after HCT, 20 weeks after the ﬁrst sensitized DLI, 20
weeks after the second sensitized DLI, and at 3 years
after HCT. Liver biopsies were performed under gen-
eral anesthesia and ultrasound guidance.
Serum Chemistry. Serum samples from dogs were
collected before HCT and thereafter at least once a
week for the ﬁrst month, once every other week for
the second month, and then at 3- to 4-month intervals
to measure concentrations of total bilirubin, direct
bilirubin, lactic dehydrogenase (LDH), glutamic-
pyruvic transaminase (SGPT), -glutamyl transpepti-
dase, and alkaline phosphatase. Erythrocyte PK activ-
ity was also measured before HCT, 25 weeks after
transplantation, 20 weeks after sensitized DLI, 20
weeks after a second sensitized DLI, and 3 years after
HCT.
Sensitization of the Stem Cell Donor and
Collection of Lymphocytes for Infusion
Donors were sensitized against recipient minor
histocompatibility antigens (mHA) by subcutaneous
placement of two 2-cm skin grafts from the recipient
dog onto the bilateral ﬂanks [9]. The skin grafts were
performed once a week for 4 consecutive weeks.
Within 7 days after the fourth skin graft, the donors
underwent Cobe-apheresis collection of mononuclear
cells. The leukapheresis product from the sensitized
donor was administered intravenously on the same day
as the collection. Before infusion, the CD3	 content
of the leukapheresis product was determined by ﬂuo-
rescence-activated cell-sorter analysis (Becton Dickin-
son, San Jose, CA) by using anti-CD3 ﬂuorescein-
conjugated monoclonal antibody 17.6F9.
Engraftment and Chimerism Study
Marrow engraftment was assessed by sustained
recoveries of granulocyte and platelet counts after the
postirradiation nadirs, by histologic features of the
marrow from biopsy, and by documentation of donor
cells in the marrow (including red blood cell precur-
sors) and among granulocytes and mononuclear cells
from the peripheral blood by using polymorphic mi-
crosatellite markers in a polymerase chain reaction–
based assay [16]. The microsatellite marker technique
detected 2.5% to 97.5% mixtures of donor and host
cells. Peripheral blood cells were separated by Ficoll-
Hypaque density gradient. Red blood cell precursors
were isolated by cell sorting (Vantage; Becton Dick-
inson) on CD45-negative/dim and CD71-positive
cells, which represented cells at an intermediate stage
of erythroid development [8,17]. Canine CD45 anti-
body (CA12.10C12) was obtained from P.F. Moore
(University of California, Davis, CA). The CD71 an-
tibody against the human transferrin receptor
(DAKO, Carpinteria, CA) stains canine marrow cells.
Assessment of Treatment Effect
Correction of disease manifestations after trans-
plantation was assessed by evaluating hematocrits, re-
ticulocyte counts, LDH, bilirubin, marrow and liver
iron stored, and marrow and liver histology [18,19].
Complete resolution of hemolysis was deﬁned as nor-
malization of reticulocyte counts (
2%) and of hema-
tocrits (37%-51%) and normal myeloid-erythroid
(M:E) ratios in the marrow. A partial response was
considered when 2 criteria were met: a50% increase
in hematocrit and a 50% reduction in reticulocyte
counts. Tissue iron concentrations were determined
on fresh samples by a bichromatic end point with a
DuPont Dimension Analyzer (DuPont, Wilmington,
DE) [18]. Gomori trichrome stain was used for ﬁbro-
sis evaluation. Marrow ﬁbrosis was classiﬁed as grade
1 (25% ﬁbrosis), 2 (50% ﬁbrosis), 3 (75% ﬁbrosis),
and 4 (100% ﬁbrosis) [19].
RESULTS
Clinical Status of Dogs before HCT
The baseline characteristics of the PK-deﬁcient
dogs are summarized in Table 1. All dogs had evi-
dence of hemolysis, with markedly decreased hemat-
ocrits and increased reticulocyte counts. Serum LDH
levels were increased from 868 to 1605 U/L (median,
1049 U/L), reﬂecting the presence of the hemolytic
process. The liver enzymes and serum bilirubin levels
were within the normal range. Haptoglobin levels
were low. Erythrocyte PK activity was normal. Mar-
rows were hypercellular with mild to moderate ﬁbro-
A. Takatu et al.
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sis (grade 1). The M:E ratio was increased in all 3
dogs.
Nonmyeloablative HCT
Nonhematopoietic Toxicities and Graft-versus-Host
Disease. Nonmyeloablative HCT was well tolerated.
Two dogs showed mild increases in liver enzyme lev-
els (SGPT and alkaline phosphatase) in the ﬁrst 4 to 6
weeks after transplantation; this may have been related
to cyclosporine. No other toxicities or signiﬁcant
changes in serum chemistries were seen. None of the
dogs developed acute or chronic graft-versus-host dis-
ease (GVHD).
Hematopoietic Engraftment and Response after HCT.
All 3 dogs showed sustained allogeneic engraftment
after HCT (Figure 1). One dog (E919) had sustained
mixed hematopoietic chimerism (60% donor chi-
merism) in the granulocyte fraction of the peripheral
blood (Figure 1B). The other 2 dogs (E854 and E920)
achieved 50% donor chimerism early after trans-
plantation, but this decreased to 
5% before the ﬁrst
DLI (Figure 1A and C). The levels of donor chimer-
ism in the peripheral blood mononuclear cell (PBMC)
fraction were sustained in all 3 dogs at 5% to 30%
(Figure 1A-C). Clinical improvement was noted ini-
tially in all 3 dogs, with hematocrits increased to 40%
(normal range, 37%-51%) and reticulocyte counts de-
creased to 1% (the normal range for dogs is 0%-2%).
However, the late decreases in myeloid chimerism in
2 dogs (E854 and E920) were associated with recur-
Table 1. Clinical Status of PK-Deﬁcient Dogs before and after Nonmyeloablative HCT and DLI
Dog No.
Age
(mo)
Hematocrit*
(%)
Reticulocytes†
(%)
LDH‡
(U/L)
Bilirubin§
(mg/dL)
PK Activity
(U/g hemoglobin)
Iron in
Marrow¶
(g/g)
Degree
of
Marrow
Fibrosis#
(0-4)
Marrow
M:E** Ratio
Liver
Histology
Liver
Iron
(g/g)††
Before
transplantation
E854 7 18.7 43.4 868 0.3 9.8 135 1 1:1 ND ND
E919 11 21.4 16.0 1605 0.4 12.5 225 1 Not reported ND ND
E920 11 27.8 30.0 673 0.3 22.5 477 1 1:5 ND ND
25 wk after
nonmyeloablative
transplantation
and before
the first DLI
E854 13 18.2 9.9 ND ND 37.9 882 1 2:1 ND ND
E919 17 43.1 3.1 1028 0.1 4.9 166 1 3:2 ND ND
E920 17 27.7 10.2 1451 0.2 9.6 1101 1 3:2 ND ND
20 wk after the
first sensitized
DLI and
before the
second DLI
E854 19 35.3 3.8 717 0.1 9.5 122 ND ND ND ND
E919 22 45.6 0.7 380 0.1 5.5 241 ND ND ND ND
E920 22 40.3 1.0 668 0.2 2.4 582 ND ND ND ND
After the second
sensitized
DLI: last
follow-up
E854 45 41.4 0.4 126 0.1 8.4 318 0-1 5:1 Normal;
grade
0
fibrosis
1826
E919 47 47.1 1.8 250 0.1 7.9 273 0 3:2 Normal;
grade
0
fibrosis
877
E920 47 44.8 0.6 163 0.1 6.4 697 0-1 3:2 Normal;
grade
0-1
fibrosis
1729
*Normal range for dogs, 37% to 51%.
†Normal range for dogs, 0% to 2.0%.
‡Normal range, 90 to 250 U/L.
§Normal range for dogs, 0 to 0.3 mg/dL.
Normal range, 9.0 to 22.0 U/g hemoglobin.
¶Normal range, 530 to 900 g/g.
#Marrow ﬁbrosis was classiﬁed as grade 0 (none), 1 (25% ﬁbrosis), 2 (50% ﬁbrosis), 3 (75% ﬁbrosis), and 4 (100% ﬁbrosis).
**Normal M:E ratio, 3:2 to 5:1.
††Normal values obtained from 6 control dogs were 700 to 1700 g/g for liver.
DLI indicates donor lymphocyte infusion; HCT, hematopoietic cell transplantation; ND, not done; LDH, lactic dehydrogenase; PK, pyruvate
kinase.
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rence of the hemolytic anemia (evidenced by decreases
in hematocrits and increases in the reticulocyte
counts). Dogs were observed for a minimum of 25
weeks before the ﬁrst mHA-sensitized DLI.
DLI: Effect on Chimerism Levels and
Manifestations of Hemolysis
At the time of the ﬁrst DLI, hemolysis associated
with decreases in the donor chimerism of the granu-
locyte fraction to
5% had recurred in 2 of the 3 dogs
(Table 1; Figure 2). Before DLI, donors were sensi-
tized to recipient-speciﬁc mHA by grafting skin from
the HCT recipient.
With the ﬁrst infusion of lymphocytes from the
respective sensitized donors, dogs E854, E919, and
E920 received 2.14, 1.80, and 2.70  108 CD3	cells
per kilogram from their respective sensitized donor.
At 18 to 22 weeks after the ﬁrst DLI, 1 dog (E920) had
a substantial increase in donor chimerism in the gran-
ulocyte fraction to 60% that was associated with an
increase in the hematocrit to 40% and a decrease in
the reticulocyte count. No substantial changes oc-
curred in the level of donor chimerism in the granu-
locyte or PBMC fractions in the other 2 dogs.
Because of persistent mixed chimerism in all 3
dogs and the persistence of hemolysis in 1 dog (E854)
with 
5% chimerism, a second sensitized DLI was
performed (Table 1). Donors were sensitized with
serial skin grafts from the recipient for the second
time. Dogs E854, E919, and E920 then received 1.28,
1.33, and 0.67  108 CD3	 cells per kilogram, re-
spectively. Dog E854 converted to full donor chimer-
ism (98%) in the granulocyte fraction within 5 weeks
after the second sensitized DLI (Figures 1A and 2).
The other 2 dogs remained mixed chimeras, with
donor contributions ranging from 47% to 62% in
marrow, 50% to 69% in granulocyte fractions, and
16% to 25% in lymphocyte fractions until last follow-
up. A population of red blood cell progenitors en-
Figure 1. Donor chimerism levels in the granulocyte and mononu-
clear fractions of the peripheral blood, hematocrit, and reticulocyte
counts across time after transplantation. Early after nonmyeloablative
stem cell transplantation in 3 dogs with pyruvate kinase deﬁciency and
hemolytic anemia, the levels of donor chimerism in the myeloid com-
partment (granulocyte fraction) decreased in 2 dogs (E854 and E920)
with a recurrence of hemolytic anemia. All dogs had 2 infusions of
donor lymphocytes (2), and both dogs with the recurrence of hemo-
lytic anemia had an increase in donor chimerism in the myeloid
compartment and resolution of hemolytic anemia. In (A), (B), and (C),
the hematocrit, reticulocyte count, and levels of donor chimerism in
the peripheral blood mononuclear cell (PBMC) and granulocyte frac-
tions are shown over time for dogs E854, E919, and E920, respectively.
● indicates hematocrit; , reticulocytes; , donor chimerism in the
granulocyte fraction; , donor chimerism in the PBMC fraction.
Figure 2. A representative sample of microsatellite marker studies
of donor and recipient (E854) cells before transplantation and
recipient cells after transplantation. After second donor lymphocyte
infusion (DLI), there was a rapid conversion to complete donor
chimerism (as noted in Figure 1A). G indicates peripheral blood
granulocyte fraction; M, peripheral blood mononuclear cell frac-
tion.
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riched for CD71 (transferrin receptor) was positively
selected by ﬂow cytometric cell sorting, DNA was
extracted, and the percentage of donor chimerism was
assessed. The level of donor chimerism was 99%,
50%, and 40% for E854, E919, and E920, respec-
tively. These levels of chimerism were comparable to
those noted in the granulocyte fraction of the periph-
eral blood for each of the dogs. All dogs showed
clinical improvement, with increases in the hematocrit
to 50% and sustained decreases in the reticulocyte
counts to normal levels.
The clinical status of the dogs at 3 years after
HCT and 2 years after the second DLI is described in
Table 1. All 3 dogs had normal hematocrits and re-
ticulocyte counts. Haptoglobin, LDH, and bilirubin
levels were normal in all 3 dogs at last follow-up.
Serum SGPT, -glutamyl transpeptidase, and alkaline
phosphatase levels remained normal in general, al-
though E854 had a mild increase in SGPT 1 year after
HCT that persisted intermittently until the last fol-
low-up (
2 times normal; E920 had an increased level
after liver biopsy). Although PK activity was mea-
sured, these levels remained at normal levels and were
not informative for the presence of recipient red blood
cells affected by the inherited PK deﬁciency disorder.
Three years after HCT, marrow cellularity and the
M:E ratio in the marrow were normal (Figure 3).
Minimal levels of marrow ﬁbrosis persisted but had
improved compared with the baseline evaluations.
Marrow iron contents remained within normal levels.
There were normal liver histologies in all dogs (Figure
4), with only minimal ﬁbrosis noted in 1 dog. Liver
iron content was mildly increased compared with con-
trols.
DISCUSSION
Inherited red blood cell diseases, including PK
deﬁciency, have been cured or stabilized by allogeneic
marrow transplantation after conventional high-dose
conditioning regimens [20]. The goal of marrow
transplantation in these diseases has been the com-
plete replacement of the defective cells with normal
red blood cells. However, the toxicities from the my-
eloablative conditioning regimen required for the in-
duction of complete donor hematopoietic chimerism
have resulted in signiﬁcant morbidity and mortality.
More recently, it has been demonstrated that estab-
lishing mixed hematopoietic donor chimerism at sub-
stantial levels in patients with sickle cell disease or
thalassemia may be sufﬁcient for reducing transfusion
requirements and complications from the disease
[21,22]. We had previously shown in this canine
model of hemolytic anemia secondary to PK deﬁ-
ciency that stable mixed chimerism could be induced
after nonmyeloablative HCT, but if donor chimerism
was less than 15% to 20%, resolution of the hemolysis
Figure 3. Marrow histology from a pyruvate kinase–deﬁcient dog
(E920) at baseline (A) and 3 years after nonmyeloablative transplan-
tation and DLI (B). A, The marrow is hypercellular with a reversed
M:E ratio. B, The marrow is normocellular with a normal M:E ratio
and maturation of all 3 major cell lines. The vacuoles seen in B are
fat cells that are observed in normocellular marrows from dogs
(stain, periodic acid–Schiff; magniﬁcation, 300).
Figure 4. Normal liver histology in a pyruvate kinase–deﬁcient dog
(E920). Three years after nonmyeloablative transplantation, there
were normal hepatocytes (large arrow) and bile ducts (small arrow).
Iron deposition was normal. There was no development of signif-
icant liver disease from iron overload, which is normally associated
with the natural history of pyruvate kinase deﬁciency in affected
dogs.
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was not achieved [8]. In this study, it was shown that
DLI after nonmyeloablative HCT was capable of
achieving complete or a high level of donor hemato-
poietic chimerism with complete resolution of the
hemolytic anemia.
After nonmyeloablative HCT, all 3 dogs had a
stable level of donor chimerism (5%-30%) in the
PBMC fraction, but before DLI 1, 2 of the 3 dogs had
had substantial decreases in donor chimerism in the
myeloid compartment to 
5%, with relapse of the
hemolytic anemia. These decreases in donor chimer-
ism after nonmyeloablative HCT without graft rejec-
tion suggested host resistance to the hematopoietic
cell graft, possibly related to the hyperproliferative
state of the recipient. After 2 infusions of recipient
mHA-speciﬁc donor lymphocytes, 1 dog converted to
complete donor chimerism (98%), a second dog
achieved a higher level of donor chimerism in the
granulocyte fraction (60%), and a third dog (already
with substantial mixed hematopoietic chimerism) had
no change in donor chimerism in either the granulo-
cyte or PBMC fraction. All 3 dogs had sustained
resolution of the hemolytic anemia, with increases of
hematocrits to normal and decreases in the reticulo-
cyte counts and serum LDH. Marrow histology be-
came normal. Iron stores were normal or only mildly
increased. In a disease process that would otherwise
inevitably lead to liver cirrhosis, there was normal
liver histology at 3 years after HCT. Erythrocyte PK
activity was not informative in this study because the
assay on the R-type isoenzymes was not performed.
PK-deﬁcient dogs have high in vitro erythrocyte PK
activity from the M2-type PK isoenzyme, which is
normally present in all tissues during fetal life and
remains the major enzyme in erythroid precursors
[10,23]. The R-type isoenzyme normally seen in ma-
ture red blood cells is absent, and the compensatory
increase in the M2-type PK isoenzyme is not sufﬁcient
to prevent hemolysis. This is the ﬁrst study in a large-
animal model of an inherited red blood cell disease in
which nonmyeloablative HCT followed by allogeneic
cell therapy led to the establishment of effective levels
of donor chimerism and a normal hematocrit without
further evidence of signiﬁcant hemolysis.
In studies of mice with inherited hemolytic disor-
ders, normal red blood cells derived from donor he-
matopoietic stem cells in a mixed chimeric state may
have an advantage contributing to the erythroid lin-
eage compared with the genetically compromised
cells. When large numbers of marrow cells from nor-
mal mice of the CBA strain (CBA	/	) were injected
into congenic PK-deﬁcient mice with severe hemo-
lytic anemia and splenomegaly without conditioning,
the red blood cell numbers and PK activity of the
mature red blood cells at 15 weeks were improved
[24]. In other studies, normal donor cells transplanted
in small numbers were sufﬁcient to correct murine
-thalassemia [25,26]. Establishment of stable mixed
chimerism after nonmyeloablative conditioning cor-
rected the anemia in the murine model of sickle cell
disease [27,28]. Engrafted mice with stable mixed chi-
merism demonstrated a higher level of donor chimer-
ism in the red blood cell compartment than that mea-
sured in peripheral blood leukocytes. Partial
correction of the anemia was observed in mice with
levels of donor chimerism in the leukocytes of
2.5%,
resulting in donor chimerism of 10% to 54% in the
red blood cell compartment [27]. In another murine
model of sickle cell disease, 70% normal myeloid
chimerism was required to fully reverse the anemia.
The higher levels of donor chimerism in peripheral
red blood cells compared with leukocytes were likely
related to the increased clearance of sickle red blood
cells compared with normal mature red blood cells
from the circulation. The observations in murine
models of inherited red blood cell diseases after HCT
are consistent with the observations made in the ca-
nine model of hemolytic anemia secondary to PK
deﬁciency, in which higher donor chimerism levels in
the leukocytes were associated with resolution of he-
molysis and correction of the anemia. There was not
an enrichment of the donor contribution to chimerism
in red blood cell precursors. Although experience is
still limited in the dog model, levels of donor chimer-
ism less than 15% to 20% were associated with per-
sistent hemolysis.
The presence of stable mixed hematopoietic chi-
merism after conventional conditioning and marrow
transplantation from HLA-identical siblings has been
associated with beneﬁcial effects in patients with
-thalassemia and sickle cell disease. Patients with
-thalassemia who had leukocytes of donor origin as
low as 20% had 80% to 95% normal -globin chain
synthesis [22,29]. The low percentages of donor leu-
kocytes, as determined by microsatellite markers or
ﬂuorescent in situ hybridization analysis for the Y
chromosome, were associated with much higher per-
centages of donor cells (fully differentiated) in the
erythroid compartment. In a study of allogeneic HCT
after conventional conditioning for sickle cell disease,
5 patients developed stable mixed chimerism [21]. In
all 5 patients, there was a substantial reduction in
hemoglobin S, and none of the patients experienced
complications from sickle cell disease after the trans-
plantation. Serial studies in 1 patient revealed the
presence of 10% to 20% donor cells in the peripheral
blood leukocytes and 70% hemoglobin A (which
was stable for 3 years) in the red blood cells. However,
donor chimerism of
5% would not be expected to be
associated with resolution of the signs and symptoms
associated with inherited red blood cell diseases. In
this setting, therapy to increase the level of donor
chimerism in the myeloid compartment may be of
beneﬁt. Although there was up to a 24% recurrence of
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host cells in a report of 3 patients with thalassemia
after myeloablative conditioning and allogeneic HCT,
DLI resulted in conversion to complete donor chi-
merism [30].
Although there are potential beneﬁts to the estab-
lishment of higher levels of donor chimerism with
DLI after nonmyeloablative conditioning if symptoms
of the inherited red blood cell disease persist, there are
risks of GVHD and aplasia. GVHD may occur in as
many as 60% of patients with relapsed CML after
conventional HCT given DLI from nonsensitized do-
nors [31,32]. To convert to complete donor hemato-
poietic chimerism in the dog model after nonmyelo-
ablative conditioning and T cell–replete marrow
transplantation, lymphocytes from the marrow donor
that have been sensitized to recipient-speciﬁc mHA
are required [9]. This is in contrast to converting
mixed to full chimerism in dogs after myeloablative
conditioning and T cell–depleted marrow transplan-
tation. In the latter case, conversion to full hemato-
poietic chimerism did not require the use of lympho-
cytes from a sensitized donor [33]. In this study of
nonmyeloablative HCT and DLI in the canine model
of hemolytic anemia, none of the 3 dogs developed
any complications secondary to DLI, and only 1 of the
dogs achieved full hematopoietic chimerism. Because
the dogs had to be bred for the genetic trait of PK
deﬁciency from a limited number of affected dogs,
there may have been less mHA disparity from which
to generate an alloreaction. We previously reported
on the experience of converting stable mixed to com-
plete donor chimerism in 8 healthy dogs after nonmy-
eloablative transplantation with mHA-sensitized DLI
[9]. All 8 recipients achieved conversion of donor
chimerism to 98% within 2 to 12 weeks of the
sensitized DLI. Complications from mHA-sensitized
DLI were observed in 3 of the 8 recipients. Two dogs
developed GVHD, of which only 1 required treat-
ment. The third dog developed marrow aplasia and
persistent pancytopenia. The incidence of complica-
tions after mHA-sensitized DLI in the dog model is
comparable to that observed in humans from nonsen-
sitized donors. A strategy to limit the risk of develop-
ing severe GVHDmay include starting with low doses
of CD3	 T cells and then increasing in a stepwise
fashion [34]. Future strategies to improve the safety of
DLI may include the use of donor T cells genetically
modiﬁed to express a suicide gene [35].
We have established proof of principle that the
combination of nonmyeloablative HCT and delayed
DLI for those recipients with low levels of donor
hematopoietic chimerism is an effective strategy for
the treatment of inherited red blood cell diseases. It is
not proposed that clinical studies be conducted with
DLI collected from donors sensitized to recipient an-
tigens. This method was used to overcome the sup-
pressor mechanism proposed to exist in recipients
with mixed hematopoietic chimerism that suppressed
the activity associated with DLI from a nonsensitized
donor [9]. Other approaches for changing the levels of
donor chimerism after DLI from nonsensitized do-
nors that would be more feasible for future clinical
studies are being investigated. In the clinic, efforts are
still required to understand and overcome the prob-
lems of rejection and GVHD after nonmyeloablative
HCT. For those patients with inherited red blood cell
disorders, transfusion-induced sensitization may in-
crease the risk of graft rejection. Further studies are
needed to improve the safety of DLI for future clinical
application, including better strategies for the man-
agement of GVHD.
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